Study Explores Low Toxicity of Onco-Innovations' PNKP Technology

Onco-Innovations Limited announced promising findings on its second-generation PNKP compound combined with radiation therapy. Conducted by researchers at the University of Alberta, the 2021 study showed effective targeting of cancer cells in mice, maintaining a low toxicity profile.

In the study, mice with colorectal cancer tumors were divided into three groups, receiving varied treatments over 24 days. Results indicated no significant signs of toxicity, suggesting potential for fewer side effects.

This could advance safer cancer therapies, aligning with Health Canada’s rigorous testing standards. CEO Thomas O'Shaughnessy highlighted the significance of these findings in developing treatments with a strong safety profile.